AbCellera Biologics Inc. (ABCL) stock analysis

ABCL · AbCellera Biologics Inc.

Latest recorded price: USD 11.12

Sector and industry: Healthcare · Biotechnology

Fiscal 2025 figures: revenue growth -46.3%, free cash flow margin -231.7%, ROIC -84.7%. The model flags 2 risk signals for this company (1 high severity).

Similar companies in Healthcare